TEVIMBRA
GrowthmAbtislelizumab-jsgr
BLASOLUTIONINJECTION
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TEVIMBRA (tislelizumab-jsgr) is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2024.
Drug data last refreshed Yesterday
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.